Nanomagnetomedizin

This article describes how magnetic nanoparticles (MNP) act as carriers for chemotherapeutics and nucleic acids (e.g., genes) and their accumulation in the target tissue (tumor) through the application of external magnetic fields (magnetic drug targeting). The aim is a localized and more efficient therapy with fewer side effects. The accumulation of MNP can be monitored by "superconducting quantum interference devices" (SQUID technology) and magnetic resonance imaging. Proof of principle of this strategy could be demonstrated with cytostatics as well as with nucleic acids, but for successful medical application further improvements are required. Ongoing research efforts are dedicated to developing advanced magnetic formulations which are mutually adapted with an optimized magnetic field technology.